NXGL Quote, Financials, Valuation and Earnings

OrthoPediatrics has a net margin of -25.37% compared to NexGel's net margin of -20.34%. NexGel's return on equity of -59.55% beat OrthoPediatrics's return on equity of -11.21%.

NexGel has a consensus price target of $6.00, signalling upside risk potential of 154.24%. On the other hand OrthoPediatrics has an analysts' consensus of $36.43 which suggests that it could grow by 79.54%. Given that NexGel has higher upside potential than OrthoPediatrics, analysts believe NexGel is more attractive than OrthoPediatrics.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison OrthoPediatrics has a beta of 1.084, suggesting its more volatile than the S&P 500 by 8.356%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OrthoPediatrics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. OrthoPediatrics pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $2.8M, which are smaller than OrthoPediatrics quarterly revenues of $52.4M. NexGel's net income of -$712K is higher than OrthoPediatrics's net income of -$10.7M. Notably, NexGel's price-to-earnings ratio is -- while OrthoPediatrics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 1.60x versus 2.21x for OrthoPediatrics. Usually stocks with elevated PS ratios are considered overvalued.

Innovative Eyewear has a net margin of -25.37% compared to NexGel's net margin of -391.35%. NexGel's return on equity of -59.55% beat Innovative Eyewear's return on equity of -97.69%.

NexGel has a consensus price target of $6.00, signalling upside risk potential of 154.24%. On the other hand Innovative Eyewear has an analysts' consensus of $7.00 which suggests that it could grow by 98.3%. Given that NexGel has higher upside potential than Innovative Eyewear, analysts believe NexGel is more attractive than Innovative Eyewear.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innovative Eyewear has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innovative Eyewear offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. Innovative Eyewear pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $2.8M, which are larger than Innovative Eyewear quarterly revenues of $454.5K. NexGel's net income of -$712K is higher than Innovative Eyewear's net income of -$1.8M. Notably, NexGel's price-to-earnings ratio is -- while Innovative Eyewear's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 1.60x versus 3.97x for Innovative Eyewear. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of -25.37% compared to NexGel's net margin of --. NexGel's return on equity of -59.55% beat Plus Therapeutics's return on equity of --.

NexGel has a consensus price target of $6.00, signalling upside risk potential of 154.24%. On the other hand Plus Therapeutics has an analysts' consensus of $10.00 which suggests that it could grow by 5054.64%. Given that Plus Therapeutics has higher upside potential than NexGel, analysts believe Plus Therapeutics is more attractive than NexGel.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.645, suggesting its less volatile than the S&P 500 by 35.542%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $2.8M, which are larger than Plus Therapeutics quarterly revenues of --. NexGel's net income of -$712K is higher than Plus Therapeutics's net income of -$17.4M. Notably, NexGel's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 1.60x versus 0.32x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Staar Surgical has a net margin of -25.37% compared to NexGel's net margin of -127.29%. NexGel's return on equity of -59.55% beat Staar Surgical's return on equity of -17.97%.

NexGel has a consensus price target of $6.00, signalling upside risk potential of 154.24%. On the other hand Staar Surgical has an analysts' consensus of $19.10 which suggests that it could grow by 16.89%. Given that NexGel has higher upside potential than Staar Surgical, analysts believe NexGel is more attractive than Staar Surgical.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Staar Surgical has a beta of 0.632, suggesting its less volatile than the S&P 500 by 36.76%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Staar Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. Staar Surgical pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $2.8M, which are smaller than Staar Surgical quarterly revenues of $42.6M. NexGel's net income of -$712K is higher than Staar Surgical's net income of -$54.2M. Notably, NexGel's price-to-earnings ratio is -- while Staar Surgical's PE ratio is 49.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 1.60x versus 2.90x for Staar Surgical. Usually stocks with elevated PS ratios are considered overvalued.